Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 in Cystic Fibrosis with F508del Mutation
2020-005805-25Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of galicaftor, navocaftor and ABBV-119 in cystic fibrosis (CF), sponsored by AbbVie Inc. Primary endpoint: Absolute change from baseline through Day 29 in percent predicted FEV1 (ppFEV1). Started Jul 2021; status: completed.
02
Drugs
galicaftornavocaftorABBV-119
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2020-005805-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005805-25.